Vera Therapeutics, Inc.’s share price was $45.11 on January 28th. The company focuses on developing biologic therapies for autoimmune diseases, with a key asset, atacicept, targeting IgA nephropathy. The total addressable market for IgAN is estimated to be $10 billion in the U.S. alone, with Vera aiming to capture 15%-25% of the market.

Atacicept, Vera’s potential blockbuster drug, has shown promising Phase 3 data, leading to a Biologics License Application submission to the FDA for potential commercialization in mid-2026. Despite positive results, Vera’s stock price has not reflected the potential success of atacicept, offering a compelling risk-reward profile for investors.

Hedge funds have shown interest in Vera Therapeutics, with 36 portfolios holding the stock at the end of the third quarter. While Vera shows promise as an investment, other AI stocks may offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks with growth potential, consider exploring other options.

Read more at Yahoo Finance: Vera Therapeutics, Inc. (VERA): A Bull Case Theory